Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP4K4 | O95819 | 17/20 | 0.58 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.54 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.54 |
| ▸ | MINK1 | Q8N4C8 | 2/20 | 0.54 |
| ▸ | TNIK | Q9UKE5 | 1/20 | 0.54 |
| ▸ | NOS3 | P29474 | 1/20 | 0.48 |
| ▸ | NOS1 | P29475 | 1/20 | 0.48 |
| ▸ | NOS2 | P35228 | 1/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.47 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.46 |
| ▸ | PDE5A | O76074 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28883695 | 0.85 | MAP4K4 (0.61) | MAP4K4NOS3NOS1NOS2CHRNA7 | |
| SCHEMBL29981431 | 0.85 | MAP4K4 (0.61) | MAP4K4NOS3NOS1NOS2CHRNA7 | |
| SCHEMBL15785404 | 0.81 | MAP4K4 (0.71) | MAP4K4NOS3NOS1NOS2 | |
| SCHEMBL10017409 | 0.81 | CYP1A2 (0.50) | MAP4K4CYP1A2KCNH2MINK1TNIK | |
| SCHEMBL2976390 | 0.81 | MAP4K4 (0.62) | MAP4K4CYP1A2KCNH2MINK1TNIK | |
| SCHEMBL29361094 | 0.81 | MAP4K4 (0.71) | MAP4K4NOS3NOS1NOS2 | |
| SCHEMBL16835760 | 0.79 | MAP4K4 (0.59) | MAP4K4CYP1A2KCNH2MINK1TNIK | |
| SCHEMBL28030764 | 0.79 | MAP4K4 (0.87) | MAP4K4CYP1A2KCNH2MINK1TNIK | |
| SCHEMBL1585264 | 0.79 | MAP4K4 (0.58) | MAP4K4NOS3NOS1NOS2CHRNA7 | |
| SCHEMBL10008911 | 0.79 | MAP4K4 (0.54) | MAP4K4CYP1A2NOS3NOS1NOS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9556172-B2 | Processes for the manufacture of propane-1-sulfonic acid (3-[5-(4-chloro-phenyl)-1H-pyrrolo[2,3-b]pyridine-3-carbonyl]-2,4-difluoro-phenyl)-amide | HOFFMAN LA-ROCHE INC. (US) | 2017-01-31 | — | — | US | disclosed |
| US-9556172-B2 | Processes for the manufacture of propane-1-sulfonic acid (3-[5-(4-chloro-phenyl)-1H-pyrrolo[2,3-b]pyridine-3-carbonyl]-2,4-difluoro-phenyl)-amide | HOFFMAN LA-ROCHE INC. (US) | 2017-01-31 | — | — | US | disclosed |
| US-20160083378-A1 | NOVEL PROCESSES FOR THE MANUFACTURE OF PROPANE-1-SULFONIC ACID (3-[5-(4-CHLORO-PHENYL)-1H-PYRROLO[2,3-b]PYRIDINE-3-CARBONYL]-2,4-DIFLUORO-PHENYL)-AMIDE | HOFFMANN LA ROCHE (US) | 2016-03-24 | — | — | US | disclosed |
| US-9150594-B2 | Processes for the manufacture of propane-1-sulfonic acid {3-[5-(4-chloro-phenyl)-1H-pyrrolo[2,3-b]pyridine-3-carbonyl]-2,4-difluoro-phenyl}-amide | HOFFMANN-LA ROCHE INC. (US) | 2015-10-06 | — | — | US | disclosed |
| US-20140288308-A1 | NOVEL PROCESSES FOR THE MANUFACTURE OF PROPANE-1-SULFONIC ACID -AMIDE | HOFFMANN LA ROCHE (US) | 2014-09-25 | — | — | US | disclosed |
| US-8779150-B2 | Processes for the manufacture of propane-1-sulfonic acid {3-[5-(4-chloro-phenyl)-1 H-pyrrolo[2,3-b]pyridine-3-carbonyl]-2,4-difluoro-phenyl}-amide | HOFFMANN-LA ROCHE INC. (US) | 2014-07-15 | — | — | US | disclosed |
| US-8349844-B2 | Substituted pyrazolo [1,5-A] pyrimidines as metabotropic glutamate antagonists | HOFFMANN-LA ROCHE INC. (US) | 2013-01-08 | — | — | US | disclosed |
| US-20120041002-A1 | SUBSTITUTED PYRAZOLO [1,5-A] PYRIMIDINES AS METABOTROPIC GLUTAMATE ANTAGONISTS | GATTI MCARTHUR SILVIA (CH) | 2012-02-16 | — | — | US | disclosed |
| US-20120022258-A1 | Novel Processes for the manufacture of Propane-1-sulfonic acid -amide | F. HOFFMANN-LA ROCHE AG (CH) | 2012-01-26 | — | — | US | disclosed |
| US-8093263-B2 | Substituted pyrazolo [1,5-a] pyrimidines as metabotropic glutamate antagonists | HOFFMANN-LA ROCHE INC. (US) | 2012-01-10 | — | — | US | disclosed |
| EP-1934214-B1 | OXADIAZOLYL PYRAZOLO-PYRIMIDINES AS MGLUR2 ANTAGONISTS | HOFFMANN LA ROCHE (CH) | 2010-04-07 | — | — | EP | disclosed |
| US-20090143580-A1 | SUBSTITUTED PYRAZOLO [1,5-a] PYRIMIDINES AS METABOTROPIC GLUTAMATE ANTAGONISTS | MCARTHUR SILVIA GATTI | 2009-06-04 | — | — | US | disclosed |
| US-7504404-B2 | Compounds as metabotropic glutamate receptor antagonists | HOFFMANN-LA ROCHE INC. (US) | 2009-03-17 | — | — | US | disclosed |
| EP-1934214-A1 | OXADIAZOLYL PYRAZOLO-PYRIMIDINES AS MGLUR2 ANTAGONISTS | F.HOFFMANN-LA ROCHE AG (CH) | 2008-06-25 | — | — | EP | disclosed |
| WO-2007039439-A1 | OXADIAZOLYL PYRAZOLO-PYRIMIDINES AS MGLUR2 ANTAGONISTS | F.HOFFMANN-LA ROCHE AG (CH) | 2007-04-12 | — | — | WO | disclosed |
| US-20070072879-A1 | Novel compounds as metabotropic glutamate receptor antagonists | HOFFMANN-LA ROCHE INC. | 2007-03-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090143580-A1 | SUBSTITUTED PYRAZOLO [1,5-a] PYRIMIDINES AS METABOTROPIC GLUTAMATE ANTAGONISTS | GRM1, GRM2, GRM3 | MAP4K4 2097/4885CYP1A2 2375/4885KCNH2 330/4885 |
| US-20140288308-A1 | NOVEL PROCESSES FOR THE MANUFACTURE OF PROPANE-1-SULFONIC ACID -AMIDE | SULT1A1, FASN, COASY | MAP4K4 403/4885CYP1A2 55/4885KCNH2 3521/4885 |
| US-20120041002-A1 | SUBSTITUTED PYRAZOLO [1,5-A] PYRIMIDINES AS METABOTROPIC GLUTAMATE ANTAGONISTS | GRM1, GRM2, GRM3 | MAP4K4 2097/4885CYP1A2 2375/4885KCNH2 330/4885 |
| US-20160083378-A1 | NOVEL PROCESSES FOR THE MANUFACTURE OF PROPANE-1-SULFONIC ACID (3-[5-(4-CHLORO-PHENYL)-1H-PYRROLO[2,3-b]PYRIDINE-3-CARBONYL]-2,4-DIFLUORO-PHENYL)-AMIDE | ALDH18A1, PFAS, PCCA | MAP4K4 300/4885CYP1A2 47/4885KCNH2 3239/4885 |
| US-20120022258-A1 | Novel Processes for the manufacture of Propane-1-sulfonic acid -amide | SULT1A1, FASN, COASY | MAP4K4 403/4885CYP1A2 55/4885KCNH2 3521/4885 |
| US-20070072879-A1 | Novel compounds as metabotropic glutamate receptor antagonists | GRM1, GRM2, GRM3 | MAP4K4 2409/4885CYP1A2 3259/4885KCNH2 340/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.